Immuneering (IMRX) Interest Expenses (2020 - 2026)

Immuneering's Interest Expenses history runs 7 years deep, the most recent figure standing at $18.1 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 9749.53% year-over-year to $18.1 million in Q1 2026; TTM through Mar 2026 was $18.1 million, a 2303.11% increase from a year earlier, with the FY2025 full-year figure at $73.4 million, up 24.38% from the prior year.
• Interest Expenses improved to $18.1 million in Q1 2026 per IMRX's latest filing, from $189051.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $29.5 million in Q3 2025 and bottomed at $129814.0 in Q4 2022.
• The 5-year median for Interest Expenses is $5.6 million (2025), against an average of $8.3 million.
• Across the five-year window, Interest Expenses surged 18981.34% in 2022 and slumped 95.9% in 2023, its largest moves.
• Year by year, Interest Expenses stood at $129814.0 in 2022, then surged by 48.37% to $192600.0 in 2023, then slipped by 4.7% to $183546.0 in 2024, then advanced by 3.0% to $189051.0 in 2025, then surged by 9462.72% to $18.1 million in 2026.
• Per Business Quant, the three latest IMRX Interest Expenses figures stand at $18.1 million (Q1 2026), $189051.0 (Q4 2025), and $29.5 million (Q3 2025).